This German Biotech's $6.5M Seed Round Targets a Major Heart Disease Gap

Jan de Vries · 2026-08-28

Let's talk about a fresh face in the European biotech scene that's got some serious momentum. Out of Heidelberg, Germany, Revier Therapeutics has just launched and secured a significant $6.5 million Seed round. It's a story that goes beyond just another funding announcement—it's about targeting a stubborn problem in cardiometabolic health where patients are still waiting for better answers. ### The Funding and the Backers This $6.5 million seed financing was spearheaded by the KHAN Technology Transfer Fund II. They weren't alone, though. The round saw participation from High-Tech Gründerfonds (HTGF), VORNvc, and a group of private investors rallied by Revier Invest Heidelberg. It's a coalition that suggests strong regional belief in the science and the team. ### The Problem They're Solving Here's the core issue, explained by co-founder and CEO Prof. Eva van Rooij, PhD. She points out that despite all the advances in heart medicine, millions of patients dealing with specific conditions are stuck with limited options. We're talking about heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD). The current treatments often manage symptoms rather than tackling the root cause. Revier's mission is to change that by developing the next generation of medicines that go after the underlying disease biology. Their strategy hinges on a novel approach to a specific class of enzymes. They're the first to develop a therapeutic strategy that selectively targets class IIa histone deacetylases (HDACs) for cardiometabolic diseases. Think of it like a precision tool. Instead of a blunt instrument that affects everything, their orally available small molecules are designed to inhibit only the harmful activity, leaving healthy biological functions intact. ### Why This Approach is Different This is where it gets interesting. Earlier attempts at HDAC inhibition had a major drawback. As scientific founder Prof. Johannes Backs, MD, explains, first-generation inhibitors targeted multiple HDAC classes broadly. This often led to severe, dose-limiting side effects. Revier's compounds are different. They're designed to be selective, zeroing in on class IIa HDACs. The goal is a therapy that's both powerful and safe—a combination that's been elusive. Michael Hamacher, PhD, from KHAN Technology Transfer Fund II, put it well. He believes Revier's strategy has the potential to 'unlock the therapeutic promise of HDAC biology' while sidestepping the limitations of past approaches. He highlighted the exceptional leadership and deep scientific expertise as key factors that could allow the company to reshape the standard of care. ### What's Next for Revier Therapeutics So, what does a biotech startup do with $6.5 million? They put it to work, fast. The capital is earmarked for pushing forward their preclinical pipeline. Their main focus is advancing two key programs: - Their lead program targeting HFpEF. - A second program focused on ASCVD. Beyond the lab work, the funding will also help build out their operational, scientific, and clinical teams. It's about moving from a promising idea to tangible therapies for patients. For professionals watching the European startup ecosystem, especially in life sciences, Revier Therapeutics is a name to remember. They're tackling a massive unmet need with a differentiated scientific angle, and now they have the fuel to accelerate.